Taysha Gene Therapies upgraded at Goldman Sachs on...

2025-12-04 12:42:03 ET More on Taysha Gene Therapies Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential Taysha Gene Therapies: Shares Are Soaring On FDA Alignment, But Caution Is Advised Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights Taysha Gene Therapies GAAP EPS of -$0.09 in-line Read the full article on Seeking Alpha For further details see: Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset